These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 17123742

  • 1. S-Citalopram in neuroendocrine challenge-tests: serotonergic responsivity in healthy male and female human participants.
    Kuepper Y, Bausch S, Iffland J, Reuter M, Hennig J.
    Psychoneuroendocrinology; 2006 Nov; 31(10):1200-7. PubMed ID: 17123742
    [Abstract] [Full Text] [Related]

  • 2. Effects of oral racemic citalopram on neuroendocrine responses.
    Hawken ER, Owen JA, Van Vugt D, Delva NJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):694-700. PubMed ID: 16563590
    [Abstract] [Full Text] [Related]

  • 3. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests.
    Henning J, Netter P.
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):67-71. PubMed ID: 14609009
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low-dose citalopram as a 5-HT neuroendocrine probe.
    Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ.
    Psychopharmacology (Berl); 2001 May; 155(3):323-6. PubMed ID: 11432696
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects.
    Seifritz E, Müller MJ, Annen O, Nil R, Hatzinger M, Hemmeter U, Moore P, Holsboer-Trachsler E.
    J Psychiatr Res; 1997 May; 31(5):543-54. PubMed ID: 9368196
    [Abstract] [Full Text] [Related]

  • 8. Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.
    Berardelli R, Margarito E, Ghiggia F, Picu A, Balbo M, Bonelli L, Giordano R, Karamouzis I, Bo M, Ghigo E, Arvat E.
    J Endocrinol Invest; 2010 Oct; 33(9):657-62. PubMed ID: 20414043
    [Abstract] [Full Text] [Related]

  • 9. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI.
    Lowe SL, Yeo KP, Teng L, Soon DK, Pan A, Wise SD, Peck RW.
    Psychoneuroendocrinology; 2006 May; 31(4):473-84. PubMed ID: 16378695
    [Abstract] [Full Text] [Related]

  • 10. Neuroendocrine effects of citalopram infusion in anorexia nervosa.
    Mondelli V, Gianotti L, Picu A, Abbate Daga G, Giordano R, Berardelli R, Pariante CM, Fassino S, Ghigo E, Arvat E.
    Psychoneuroendocrinology; 2006 Nov; 31(10):1139-48. PubMed ID: 17045409
    [Abstract] [Full Text] [Related]

  • 11. Acute citalopram administration produces correlated increases in plasma and salivary cortisol.
    Bhagwagar Z, Hafizi S, Cowen PJ.
    Psychopharmacology (Berl); 2002 Aug; 163(1):118-20. PubMed ID: 12185409
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
    Nadeem HS, Attenburrow MJ, Cowen PJ.
    Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
    [Abstract] [Full Text] [Related]

  • 13. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study.
    Grillon C, Levenson J, Pine DS.
    Neuropsychopharmacology; 2007 Jan; 32(1):225-31. PubMed ID: 16971899
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine increases salivary cortisol in healthy volunteers.
    Chamberlain SR, Müller U, Cleary S, Robbins TW, Sahakian BJ.
    J Psychopharmacol; 2007 Jul; 21(5):545-9. PubMed ID: 17446206
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?
    Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E.
    J Clin Psychopharmacol; 1998 Oct; 18(5):390-8. PubMed ID: 9790157
    [Abstract] [Full Text] [Related]

  • 17. The citalopram challenge test in patients with major depression and in healthy controls.
    Kapitany T, Schindl M, Schindler SD, Hesselmann B, Füreder T, Barnas C, Sieghart W, Kasper S.
    Psychiatry Res; 1999 Nov 08; 88(2):75-88. PubMed ID: 10622344
    [Abstract] [Full Text] [Related]

  • 18. Effect of single doses of citalopram and reboxetine on urethral pressure: A randomized, double-blind, placebo- and active-controlled three-period crossover study in healthy women.
    Christoffersen T, Kornholt J, Riis T, Sonne J, Sonne DP, Klarskov N.
    Neurourol Urodyn; 2022 Aug 08; 41(6):1482-1488. PubMed ID: 35771361
    [Abstract] [Full Text] [Related]

  • 19. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.
    Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM.
    Int Clin Psychopharmacol; 2001 Mar 08; 16(2):75-86. PubMed ID: 11236072
    [Abstract] [Full Text] [Related]

  • 20. Contrasting effects of citalopram and reboxetine on waking salivary cortisol.
    Harmer CJ, Bhagwagar Z, Shelley N, Cowen PJ.
    Psychopharmacology (Berl); 2003 Apr 08; 167(1):112-4. PubMed ID: 12605289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.